Sonus names new president

Article

Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the

Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the company and will add chairman to his title. Martino comes to Sonus from the nuclear medicine division of Mallinckrodt of St. Louis, which has a product marketing alliance with Sonus’ rival Molecular Biosystems.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.